Certain identified information marked with [***] has been excluded from this exhibit because it is not material and is of the type that the registrant treats as private and confidential. ARCA BIOPHARMA, INC. CONSULTING AGREEMENTConsulting Agreement • April 4th, 2024 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • Colorado
This Consulting Agreement (this “Agreement”) is made and entered into as of April 3, 2024 (the “Effective Date”) by and between ARCA biopharma, Inc. (the “Company”), and Dr. Michael Bristow (“Consultant”) (each herein referred to individually as a “Party,” or collectively as the “Parties”).
SEPARATION AGREEMENT AND RELEASESeparation Agreement and Release • April 4th, 2024 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • Colorado
This Separation Agreement and Release (“Agreement”) is made by and between Michael Bristow (“Executive”) and ARCA biopharma, Inc. (formerly known as ARCA Discovery, Inc.) (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”).
